Parexel International Corporation

Global Healthcare Contract Research Outsourcing market analyzes the current and future prospects of the Healthcare Contract Research Outsourcing market worldwide. The stakeholders of this report include companies engaged in production and marketing of Healthcare Contract Research Outsourcing ...

PAREXEL International (NASDAQ: PRXL) and Celator Pharmaceuticals (NASDAQ:CPXX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, ...

With nearly 19,000 employees in 51 countries, Parexel International shepherds experimental medicines through the maze-like clinical and regulatory process, crucial work that many firms can't afford to do themselves. The multibillion-dollar global juggernaut has overseen tens of thousands of clinical drug ...

Top-10 CRO Parexel has brought in an experienced hand to take the helm. Co-founder Josef von Rickenbach — a familiar face in the outsourcing world — is stepping up to concentrate on the chairman's spot after guiding the company for the past 35 years. And he's being replaced in the CEO suite by ...

For Jamie Macdonald, former CEO of Raleigh-based contract research organization INC Research (now Syneos Health), returning to the helm of another global CRO wasn't initially in the plans. But he ended up doing just that. Waltham, Massachusetts-based Parexel – which has a sizable presence in ...

It is the end of an era and the dawn of a new one at Parexel. In 1982, von Rickenbach and chemist Anne Sayigh started Parexel as a regulatory affairs consulting firm, and over the past 35 years, it has grown into one of the world's largest biopharmaceutical contract service providers with about 18,900 ...

Last year proved to be particularly challenging to Boston-based Parexel, which had built up a global organization of some 19,000 staffers. Pamplona Capital ended up buying the company out for $5 billion after a reorganization cost more than a thousand jobs, driven by some painful cancellations the year ...

“This partnership aims to help sponsors leverage the many benefits of conducting early phase trials in South Korea, including easy and rapid access to patients, low costs, and a favorable regulatory environment,” said Stanford Jhee, PharmD, Parexel corporate vice president, early phase scientific affairs.